|
gptkbp:instanceOf
|
gptkb:antibiotic
polypeptide antibiotic
|
|
gptkbp:approvedBy
|
1948 (US)
|
|
gptkbp:ATCCode
|
D06AX09
|
|
gptkbp:availableOn
|
gptkb:hospital
injection
|
|
gptkbp:bannedIn
|
Canada (topical OTC)
|
|
gptkbp:CASNumber
|
1405-87-4
|
|
gptkbp:chemicalClass
|
peptide
|
|
gptkbp:color
|
white to off-white powder
|
|
gptkbp:compatibleWith
|
systemic infections (except rare cases)
|
|
gptkbp:contraindication
|
systemic use in kidney disease
|
|
gptkbp:discoveredBy
|
gptkb:Balbina_Johnson
|
|
gptkbp:discoveredIn
|
1945
|
|
gptkbp:eliminationHalfLife
|
6 hours (IM)
|
|
gptkbp:excretion
|
renal
|
|
gptkbp:hasMolecularFormula
|
C66H103N17O16S
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Bacitracin
|
|
gptkbp:includedIn
|
gptkb:Neosporin_(US,_older_formulations)
triple antibiotic ointment
|
|
gptkbp:legalStatus
|
gptkb:OTC
Rx-only (injection)
|
|
gptkbp:marketedAs
|
gptkb:Baci-IM
gptkb:Bacitracin_Zinc
Baciguent
|
|
gptkbp:mechanismOfAction
|
inhibits cell wall synthesis
|
|
gptkbp:meltingPoint
|
>200°C
|
|
gptkbp:metabolism
|
minimal
|
|
gptkbp:notEffectiveAgainst
|
fungi
viruses
|
|
gptkbp:notRecommendedFor
|
oral use
|
|
gptkbp:origin
|
isolated from Bacillus species
|
|
gptkbp:pregnancyCategory
|
C
|
|
gptkbp:producedBy
|
gptkb:Bacillus_licheniformis
gptkb:Bacillus_subtilis
|
|
gptkbp:PubChem_CID
|
5280960
DB00626
|
|
gptkbp:riskFactor
|
anaphylaxis
nephrotoxicity (parenteral)
|
|
gptkbp:routeOfAdministration
|
topical
intramuscular
|
|
gptkbp:sideEffect
|
gptkb:contact_dermatitis
allergic reaction
nephrotoxicity (systemic use)
|
|
gptkbp:solubility
|
water soluble
|
|
gptkbp:spectrumOfActivity
|
Gram-positive bacteria
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:UNII
|
I7G6Z7FY7H
|
|
gptkbp:usedFor
|
treatment of bacterial infections
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:BAC
|
|
gptkbp:bfsLayer
|
6
|